Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study
Background Respiratory syncytial virus (RSV) causes substantial acute lower respiratory infections (ALRI), particularly during infants’ first RSV season. This study evaluated the impact of a new long-acting monoclonal antibody, nirsevimab, on Chinese infants.Research design and methods A monthly dec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2526601 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423247975645184 |
|---|---|
| author | Xiaozhen Lai Yidi Ma Weishun Zou Samira Soudani Hai Fang |
| author_facet | Xiaozhen Lai Yidi Ma Weishun Zou Samira Soudani Hai Fang |
| author_sort | Xiaozhen Lai |
| collection | DOAJ |
| description | Background Respiratory syncytial virus (RSV) causes substantial acute lower respiratory infections (ALRI), particularly during infants’ first RSV season. This study evaluated the impact of a new long-acting monoclonal antibody, nirsevimab, on Chinese infants.Research design and methods A monthly decision-analytic model assessed nirsevimab’s impact for the 2024 birth cohort, incorporating domestic RSV-ALRI parameters. Outcomes included RSV-ALRI cases, hospitalization involving intensive care unit admission and mechanical ventilators use, in-hospital deaths and quality-adjusted life years (QALYs).Results Without intervention, a total of 873 035 RSV-ALRI cases (269 067 hospitalized), 2 125 deaths, 74 422 QALY loss and $998 million costs were estimated, where higher-risk infants (5.23% of the cohort) accounted for 8.83% of inpatient cases, 12.23% of deaths and 9.87% of costs. With 20% coverage for higher-risk and 10% for healthy term infants, nirsevimab could prevent 61 094 RSV-ALRI cases (19 905 hospitalized), 168 deaths and 5 808 QALY loss, saving $77 million. Tripling the coverage could avert 183 282 RSV-ALRI cases (59 713 hospitalized), 506 deaths and 17 425 QALY loss, saving $231 million.Conclusions Nirsevimab introduction could effectively mitigate RSV-ALRI burden in Chinese infants, and enhanced coverage is recommended to maximize the public health benefits. |
| format | Article |
| id | doaj-art-9e002ca753f347cfbe564ce1df9b5c65 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-9e002ca753f347cfbe564ce1df9b5c652025-08-20T03:30:41ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0110.1080/14760584.2025.2526601Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling studyXiaozhen Lai0Yidi Ma1Weishun Zou2Samira Soudani3Hai Fang4School of Public Health, Peking University, Beijing, ChinaSchool of Public Health, Peking University, Beijing, ChinaSanofi, Beijing, ChinaSanofi, Lyon, FrancePeking University Health Science Center-Chinese Center for Disease Control and Prevention Joint Research Center for Vaccine Economics, Peking University, Beijing, ChinaBackground Respiratory syncytial virus (RSV) causes substantial acute lower respiratory infections (ALRI), particularly during infants’ first RSV season. This study evaluated the impact of a new long-acting monoclonal antibody, nirsevimab, on Chinese infants.Research design and methods A monthly decision-analytic model assessed nirsevimab’s impact for the 2024 birth cohort, incorporating domestic RSV-ALRI parameters. Outcomes included RSV-ALRI cases, hospitalization involving intensive care unit admission and mechanical ventilators use, in-hospital deaths and quality-adjusted life years (QALYs).Results Without intervention, a total of 873 035 RSV-ALRI cases (269 067 hospitalized), 2 125 deaths, 74 422 QALY loss and $998 million costs were estimated, where higher-risk infants (5.23% of the cohort) accounted for 8.83% of inpatient cases, 12.23% of deaths and 9.87% of costs. With 20% coverage for higher-risk and 10% for healthy term infants, nirsevimab could prevent 61 094 RSV-ALRI cases (19 905 hospitalized), 168 deaths and 5 808 QALY loss, saving $77 million. Tripling the coverage could avert 183 282 RSV-ALRI cases (59 713 hospitalized), 506 deaths and 17 425 QALY loss, saving $231 million.Conclusions Nirsevimab introduction could effectively mitigate RSV-ALRI burden in Chinese infants, and enhanced coverage is recommended to maximize the public health benefits.https://www.tandfonline.com/doi/10.1080/14760584.2025.2526601Acute lower respiratory infectionsinfant healthmonoclonal antibodypublic health impactrespiratory syncytial virus |
| spellingShingle | Xiaozhen Lai Yidi Ma Weishun Zou Samira Soudani Hai Fang Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study Expert Review of Vaccines Acute lower respiratory infections infant health monoclonal antibody public health impact respiratory syncytial virus |
| title | Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study |
| title_full | Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study |
| title_fullStr | Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study |
| title_full_unstemmed | Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study |
| title_short | Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study |
| title_sort | public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among chinese infants a modelling study |
| topic | Acute lower respiratory infections infant health monoclonal antibody public health impact respiratory syncytial virus |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2526601 |
| work_keys_str_mv | AT xiaozhenlai publichealthimpactofnirsevimabagainstacutelowerrespiratoryinfectionsassociatedwithrespiratorysyncytialvirusamongchineseinfantsamodellingstudy AT yidima publichealthimpactofnirsevimabagainstacutelowerrespiratoryinfectionsassociatedwithrespiratorysyncytialvirusamongchineseinfantsamodellingstudy AT weishunzou publichealthimpactofnirsevimabagainstacutelowerrespiratoryinfectionsassociatedwithrespiratorysyncytialvirusamongchineseinfantsamodellingstudy AT samirasoudani publichealthimpactofnirsevimabagainstacutelowerrespiratoryinfectionsassociatedwithrespiratorysyncytialvirusamongchineseinfantsamodellingstudy AT haifang publichealthimpactofnirsevimabagainstacutelowerrespiratoryinfectionsassociatedwithrespiratorysyncytialvirusamongchineseinfantsamodellingstudy |